Coca-Cola Updates Guidance Amid Coronavirus Fears

Coca-Cola reaffirmed its full-year outlook, though

by Patrick Martin

Published on Feb 21, 2020 at 10:16 AM

Companies are starting to unravel how the coronavirus outbreak will affect their bottom line, and the results haven't been pretty. Coca-Cola Co (NYSE:KO) adjusted its own outlook this morning, cutting its current-quarter earnings by one to two cents per share. While China is the company's third-largest market in terms of unit case volume, Coca-Cola did reaffirm its full-year guidance.

In response, Coca-Cola stock is hanging tough today, trading flat at $59.66 while most of Wall Street sells off. KO has been on a roll to start 2020, nabbing a record high of $60.07 on Feb. 14. Although that $60 level has proven elusive, a short-term floor has emerged at the $59 level, which is also home to the shares' 20-day moving average.

For a stock that's up 32.4% in the last 12 months, analysts remain split. There are 14 brokerages in coverage of KO, and seven rate it a tepid "hold," while the consensus 12-month price target of $63.50 is a slim 6.3% premium to last nights closing perch at $59.72.

Meanwhile with earnings come and gone, a volatility crush means the stock's near-term options are attractively priced at the moment. Schaeffer's Volatility Index (SVI) stands at 14%, in the 20th percentile of its annual range. This indicates that now is an attractive time to jump aboard the Dow name with options.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.
Cannabis Stock Rally Cut Short after Downgrade
Aurora Cannabis did receive a price-target hike from Jefferies, though
Vaccines, China Trigger Roller Coaster Week for Stocks
Moderna's vaccine captured the attention of Wall Street
Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.